Join the Family

Felicis portfolio companies are growing their teams in the U.S. and beyond.

Sr. Research Associate / Scientist, Structural Biology

Genesis Therapeutics

Genesis Therapeutics

San Diego, CA, USA
Posted on Thursday, July 11, 2024
Genesis Therapeutics is pioneering artificial intelligence guided rational drug design to address severe unmet medical needs for patients. Our lab in San Diego is looking for a motivated and enthusiastic candidate to support our Structural Biology efforts. The ideal candidate will have previous hands-on experience in the acquisition and analysis of structure data from X-ray crystallography that will help drive rapid progress in our drug programs across a variety of different targets.

What You Will Do

  • Plan and execute experiments with the aim of determining small molecule protein complex structures by X-ray crystallography or CryoEM
  • Utilize high throughput crystallization platform to screen, identify and optimize crystallization conditions
  • Offers solutions to ongoing protein/crystallization problems within the group and CROs
  • Acquire a broad understanding of the various disciplines involved in drug discovery
  • Communicate results efficiently & precisely via oral communication and in written format by maintaining electronic lab notebook and preparing presentation material.
  • Work with other drug discovery disciplines (biology, DMPK, software engineers, computational chemists) to enable hypothesis driven decisions, improve the platform and contribute to the scientific excellence of the company.

What You Will Bring

  • Minimum BSc or MSc in Structural Biology, Biochemistry, Biophysics, or a related field with 5-6+ years (BSc) or 3+ years (MSc) of industry lab experience
  • Proven hands-on experience with construct design, protein expression, purification, and structural characterization by X-ray crystallography is a must.
  • Understanding of orthogonal biophysical methods to characterize protein quality and purity.
  • Familiarity with lab automation/instrumentation is preferred.
  • Knowledge of cryo-EM sample and grid preparation, map generation and structure solution would be a plus.
  • Ability to work efficiently and deliver results within timelines while maintaining a high attention to detail ensuring reliable and reproducible data generation.
  • Strong communication skills that will be applied in a team environment.
  • Motivation, critical thinking skills and ability to adapt to project changes.

What We Offer

  • Competitive Pay
  • Stock Option Eligibility
  • 401(k) Plan
  • Open PTO Policy
  • Paid Company Holidays
  • Free lunch and snacks at our offices
  • Health Care Plan, including Medical, Dental, and Vision, fully covered for the employees
Genesis Therapeutics is a pioneering AI Biotech company focusing on the discovery of novel drugs using unique approaches to both undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases.
Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. In addition, Genesis has announced two AI platform collaborations across a range of therapeutic areas with Genentech and h Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. We’ve also been featured in Forbes 30u30 and in Forbes AI 50.
Genesis originated in graph machine learning research in Vijay Pande’s lab at Stanford, when it was joined by legendary drug hunters and biotech entrepreneurs (including Dr. Leonard Bell, founder and CEO of Alexion Pharmaceuticals, acquired by Astra Zeneca for $39Bn; and Peppi Prasit, storied chemist from Merck known for Vioxx, Arcoxia, Singulair, who then went on to found Amira Pharmaceuticals, acquired by BMS, and Inception Sciences). The company is making strong progress in expanding the domain of our AI technology with the advance of our pipeline of best-in-class and first-in-class programs, both internal targets and those in partnership with Genentech and Lilly.